| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Opthea Limited$3.41
-0.07 (-2.01%)
D 26Pipeline Score Richly Valued Biotech · Clinical
Market Cap
464.47 M
EPS
-2.32
P/E Ratio
-
Value Trade
10.20 K
0 %
Week
-36.85 %
1 Month
3.33 %
3 Month
-4.75 %
6 Month
-84.04 %
5 Year
-13.71 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
3.02 K
52 Week Range
1.79 - 6.30
% held by Insiders
-
% held by Institutions
5.05 %
Enterprise Value
6.44 B
Total Shares
153.89 M
Short %
0.64 %
Float Shares
785.87 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-02-12 | Sozinibercept | Phase 2b data readout | Phase 2b | — | – | – | – |
2025-02-12 | Sozinibercept | Phase 2b data readout | Phase 2b | — | – | – | – |
2025-02-12 | Sozinibercept | Phase 2b data readout | Phase 2b | — | – | – | – |
Drug Pipeline Intelligence
D26
Pipeline Score $13M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 27%
Micro Cap (rank 675 of 923)
Percentile RankOpthea Limited faces pipeline headwinds (26/100), with $273M risk-adjusted pipeline value, led by OPT-302 in Neovascular Age-related Macular Degeneration (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPT-302 Monoclonal antibody | Neovascular Age-related Macular Degeneration | Phase 2 | NCT03345082 | 22% | $246M | COMPLETED | 366 | - | - | May 14, 2019 | - | Jan 12, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
sozinibercept Fast Track | wet AMD | Phase 3 | 2025-03-31 | 4 week dosing: mean change bcva 13.3, n 301, ranibizumab mean change 14.2, p value 0.35; 8 week dosing: mean change bcva 12.9, n 301, ranibizumab mean change 14.2, p value 0.19; overall population 4 week: mean change bcva 13.3, n 328, ranibizumab mean change 14.3, p value 0.32; overall population 8 week: mean change bcva 12.6, n 326, ranibizumab mean change 14.3, p value 0.09 Read More | Opthea Announces Decision to Discontinue Wet AMD Trials | |
sozinibercept Fast Track | wet AMD | Phase 3 | 2025-03-31 | 4 week dosing: mean change bcva 13.3, n 301, ranibizumab mean change 14.2, p value 0.35; 8 week dosing: mean change bcva 12.9, n 301, ranibizumab mean change 14.2, p value 0.19; overall population 4 week: mean change bcva 13.3, n 328, ranibizumab mean change 14.3, p value 0.32; overall population 8 week: mean change bcva 12.6, n 326, ranibizumab mean change 14.3, p value 0.09 Read More | Opthea Announces Decision to Discontinue Wet AMD Trials | |
sozinibercept Fast Track | wet AMD | Phase 3 | 2025-03-31 | 4 week dosing: mean change bcva 13.3, n 301, ranibizumab mean change 14.2, p value 0.35; 8 week dosing: mean change bcva 12.9, n 301, ranibizumab mean change 14.2, p value 0.19; overall population 4 week: mean change bcva 13.3, n 328, ranibizumab mean change 14.3, p value 0.32; overall population 8 week: mean change bcva 12.6, n 326, ranibizumab mean change 14.3, p value 0.09 Read More | Opthea Announces Decision to Discontinue Wet AMD Trials |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OPT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OPT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How OPT ranks across every disease it competes inCompetitive Position is a premium feature
See how OPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial